Greater Cannabis Company (GCAN) Other Operating Expenses (2017 - 2026)
Greater Cannabis Company's (GCAN) quarterly Other Operating Expenses came in at $33376.0 in Q1 2026, down 23.34% year-on-year from $43536.0 in Q1 2025, and down 37.97% quarter-over-quarter from $53806.0 in Q4 2025.
Greater Cannabis Company (GCAN) Other Operating Expenses (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Other Operating Expenses history runs 10 years deep, the most recent figure standing at $33376.0 for Q1 2026.
- On a quarterly basis, Other Operating Expenses fell 23.34% year-over-year to $33376.0 in Q1 2026; TTM through Mar 2026 was $172845.0, a 7.45% increase from a year earlier, with the FY2025 full-year figure at $183005.0, up 17.1% from the prior year.
- Other Operating Expenses slipped to $33376.0 in Q1 2026 per GCAN's latest filing, from $53806.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $53806.0 in Q4 2025 and bottomed at $33376.0 in Q1 2026.
- The 5-year median for Other Operating Expenses is $42267.0 (2022), against an average of $42650.4.
- Across the five-year window, Other Operating Expenses sank 64.81% in 2022 and jumped 43.01% in 2025, its largest moves.
- Year by year, Other Operating Expenses stood at $42267.0 in 2022, then increased by 4.16% to $44027.0 in 2023, then slipped by 14.54% to $37625.0 in 2024, then soared by 43.01% to $53806.0 in 2025, then tumbled by 37.97% to $33376.0 in 2026.
- Per Business Quant, the three latest GCAN Other Operating Expenses figures stand at $33376.0 (Q1 2026), $53806.0 (Q4 2025), and $37412.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33,376.00 |
| Dec 31, 2025 | 53,806.00 |
| Sep 30, 2025 | 37,412.00 |
| Jun 30, 2025 | 48,251.00 |
| Mar 31, 2025 | 43,536.00 |
| Dec 31, 2024 | 37,625.00 |
| Sep 30, 2024 | 40,443.00 |
| Jun 30, 2024 | 39,257.00 |
| Mar 31, 2024 | 38,951.00 |
| Dec 31, 2023 | 44,027.00 |
| Sep 30, 2023 | 50,465.00 |
| Jun 30, 2023 | 41,404.00 |
| Mar 31, 2023 | 39,468.00 |
| Dec 31, 2022 | 42,267.00 |
| Sep 30, 2022 | 49,304.00 |
| Jun 30, 2022 | 43,034.00 |
| Mar 31, 2022 | 42,430.00 |
| Dec 31, 2021 | 120,102.00 |
| Sep 30, 2021 | 74,338.00 |
| Jun 30, 2021 | 62,449.00 |